The global Digital Pathology Market size is expected to reach USD 1.73 billion by 2030, registering a CAGR of 8.0% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is anticipated to witness exponential growth owing to rising prevalence of chronic diseases aided by increasing demand for accurate diagnostics. Chronic diseases affect nearly one in every three adults. Whereas, according to the CDC, in the U.S., approximately, 51.8% of adults have at least one chronic disease. Digital pathology, including molecular tissue profiling, biobanking, tissue microarray analysis, and molecular biology, plays an important role in the drug development pipeline and companion diagnostics. Growing demand for high-quality tissue samples in tissue-based biomarker research is expected to drive technology adoption over the forecast period.
Increasing
adoption of telepathology with the launch of newer versions of the technology,
such as in June 2022, Tribun Health launched TeleSlide Patho 5, an online
telepathology platform used for providing clinical and timely expertise to
patients. Moreover, the market is expected to see intense competition in the
near future as companies adopt more stringent strategies to compete. Moreover,
technological advancements, such as the digitization of pathology lab makes the
specialty more efficient, the specimen more reproducible, and pathologists'
work easier. In past few years, several breakthrough advancements have provided
a significant boost to market growth.
For
instance, in September 2021, Paige received FDA approval for Paige Prostate, an
AI solution for the detection of prostate cancer. The product is the first
AI-enabled pathology product to gain marketing authorization. This was further
followed by the collaboration of F. Hoffmann-La Roche Ltd. with Ibex in October
2021 for the development of artificial intelligence-based pathology
applications for the improvement of patient care. Furthermore, major players
are adopting strategies like collaborations and partnerships with a focus on
technological advancements, such as robotic light microscopy, digital imaging,
multiple fiber optic communications, and computerization, to enhance the
adoption of digital pathology.
For
instance, in December 2022, Deciphex launched Patholytix 3.0, a Digital Research
Pathology Platform with an aim to revolutionize tools available for research
pathologists and designed to overcome the limits of LIMS software that allows
users to effectively manage associated data and samples. Furthermore, with the
launch, the company also highlighted features of the new platform that impact
workflow and offer simpler and more expedient report creation.
List of Key Players in the Digital Pathology Market
- Leica
Biosystems Nussloch GmbH (Danaher)
- Hamamatsu
Photonics, Inc.
- Koninklijke
Philips N.V.
- Olympus
Corporation
- F.
Hoffmann-La Roche Ltd.
- Mikroscan
Technologies, Inc.
- Inspirata,
Inc.
- Epredia
(3DHISTECH Ltd.)
- Visiopharm
A/S
- Huron
Technologies International Inc.
- ContextVision
AB
- CellaVision
- HANGZHOU
ZHIWEI INFORMATION TECHNOLOGY CO. LTD. (MORPHOGO)
- West Medica
Produktions- und Handels- GmbH (West Medica)
- aetherAI
- IBEX (IBEX
MEDICAL ANALYTICS)
- SigTuple
Technologies Private Limited
- Morphle
Labs, Inc
- Bionovation
Biotech, Inc.
Related Press
Release@ Digital
Pathology Market Report
Digital Pathology Market Report Highlights
- Based on
product, The device segment held the largest share of 51.72% in 2023 and
is anticipated to grow at a lucrative growth rate during the projected
period. The device segment includes a slide management system and scanner.
The segment growth is attributed to the increasing adoption of digital
pathology in academic research activities with enhanced resolution
- Based on
application, Disease diagnosis is anticipated to witness the fastest
growth rate from 2024 to 2030 due to an increasing prevalence of chronic
diseases and demand for noble diagnosis techniques
- In terms of
end-use, The hospitals segment dominated the market in 2023 with a share
of 36.7% due to the growing incorporation of digital pathologies in
healthcare settings for efficient disease diagnosis
- North
America dominated overall market in 2023 with a share of 40.7%, due to the
presence of well-established digital infrastructure and several
technological advancements pertaining to the incorporation of technology
in healthcare settings
Request For A Free Consultation @ https://www.grandviewresearch.com/request-free-consultation/1397/rfc
Digital Pathology Market Segmentation
Grand
View Research has segmented the global digital pathology market based on
product, type, application, end-use, and region:
Digital Pathology Product Outlook (Revenue, USD Billion,
2018 - 2030)
- Software
- Device
- Scanners
- Slide
Management System
- Storage
System
Digital Pathology Type Outlook (Revenue, USD Billion,
2018 - 2030)
- Human
Pathology
- Veterinary
Pathology
Digital Pathology Application Outlook (Revenue, USD Billion,
2018 - 2030)
- Drug
Discovery & Development
- Academic
Research
- Disease
Diagnosis
- Cancer Cell
Detection
- Others
Digital Pathology End-use Outlook (Revenue, USD Billion,
2018 - 2030)
- Hospitals
- Biotech
& Pharma Companies
- Diagnostic
Labs
- Academic
& Research Institutes
Digital Pathology Regional Outlook (Revenue, USD Billion,
2018 - 2030)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- ROE
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- RoAPAC
- Latin
America
- Brazil
- Mexico
- Argentina
- RoLATAM
- Middle East
& Africa
- South
Africa
- Saudi
Arabia
- UAE
- Kuwait
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-95196
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
